CGT1263 / Cogent Biosci - LARVOL DELTA

Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS (AACR 2026) - "CGT1263 demonstrates robust anti-proliferative activity across a tumor spheroid panel of KRAS altered cell lines. In vivo characterization of CGT1815, the prodrug of CGT1263, includes steady state pharmacokinetics across species, pharmacodynamics, and efficacy in KRAS altered mouse tumor models."

Clinical • Colorectal Cancer • Oncology • HRAS • KRAS • NRAS

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) - "...'We look forward to advancing this program with the goal of filing an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in 2026.'...The poster presented today describes Cogent’s internally developed KRAS(ON/OFF) inhibitor CGT1263, showing clear selectivity over HRAS and NRAS, with picomolar (pM) activity across a broad panel of KRAS mutant cell lines. In addition, the poster also characterizes CGT1815 (the prodrug of CGT1263), which is designed to optimize human pharmacokinetic performance, supported by pharmacokinetics data from both CGT1815 and CGT1263 across multiple species."

IND • Preclinical • Solid Tumor